Alan Nicolle

Alan Nicolle’s background includes work across the fields of consultancy, global CROs, and big pharmaceutical companies before he joined MMS in 2014.

In his current position, Alan is responsible for the strategic leadership and planning of the operational side of the business. His main focus revolves around supporting and developing strategic initiatives, overseeing special projects that are of key importance, and assisting the COO with the creation of both short-term and long-term business goals. Alan collaborates closely with executive leadership and heads of all service lines to ensure alignment with the company’s key priorities. Additionally, he provides support to HR and finance functions when needed, aiming to maintain a successful business operational structure within various global regions.

Alan holds a Postgraduate Diploma in Information Technology and Society, as well as a Bachelor’s degree in Physiology and Biochemistry from the University of Southampton.

Suggested For You

perspectives

October 8th, 2024

Diversity Action Plan Guidance Part I: Implications for Sponsors

webinar

October 22nd, 2024

Optimal Strategies to Protect Commercially Confidential Information (CCI) in Clinical Documents and Report Trial Results Under Revised EU-CTIS Transparency Rules

perspectives

September 30th, 2024

Meet the Leaders Driving MMS’s European Growth

perspectives

September 30th, 2024

The Future of Data Management and Biostatistics: Trends and Technologies Shaping the Industry

perspectives

September 24th, 2024

Embracing Quality Management Maturity (QMM) at the Cornerstone of the Pharmaceutical Industry

perspectives

September 11th, 2024

From Historical Precedent to Modern Approvals: Lessons Learned on OTC Drug Products for FDA OMORs

webinar

September 26th, 2024

Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance

perspectives

September 4th, 2024

Email Security – Navigating Through the Process of Validation and Compliance with Healthcare Business Stakeholders

perspectives

August 27th, 2024

Optimizing Oncology Drug Development: FDA Expedited Pathways, Real-Time Review, and Global Programs

regulatory intelligence

August 27th, 2024

Recent Guidance on Diversity Action Planning

regulatory intelligence

August 26th, 2024

Oncology Programs at the FDA

regulatory intelligence

August 26th, 2024

Three Key Take Reflections on the Recent Donanemab Approval